Healthcare provider profile · identity verified

Mintu Mary John, MD

Internal Medicine · HIGH POINT, NC · NPI 1366904732

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	453	152
Amlodipine Besylate	Amlodipine Besylate	382	112
Lisinopril	Lisinopril	295	92
Gabapentin	Gabapentin	253	63
Levothyroxine Sodium	Levothyroxine Sodium	213	57
Losartan Potassium	Losartan Potassium	198	61
Omeprazole	Omeprazole	193	55
Rosuvastatin Calcium	Rosuvastatin Calcium	163	54
Metformin Hcl	Metformin Hcl	154	48
Metoprolol Succinate	Metoprolol Succinate	136	40
Metformin Hcl Er	Metformin Hcl	128	37
Pravastatin Sodium	Pravastatin Sodium	119	31
Albuterol Sulfate Hfa	Albuterol Sulfate	115	40
Pantoprazole Sodium	Pantoprazole Sodium	105	35
Hydrochlorothiazide	Hydrochlorothiazide	98	30
Potassium Chloride	Potassium Chloride	93	27
Allopurinol	Allopurinol	92	23
Trazodone Hcl	Trazodone Hcl	86	23
Simvastatin	Simvastatin	84	27
Duloxetine Hcl	Duloxetine Hcl	80	18
Metoprolol Tartrate	Metoprolol Tartrate	71	24
Glipizide Er	Glipizide	68	26
Lorazepam	Lorazepam	68	suppressed
Famotidine	Famotidine	67	27
Fluticasone Propionate	Fluticasone Propionate	67	31
Furosemide	Furosemide	66	23
Montelukast Sodium	Montelukast Sodium	66	26
Ozempic	Semaglutide	59	12
Sertraline Hcl	Sertraline Hcl	57	19
Alendronate Sodium	Alendronate Sodium	54	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	54	23
Escitalopram Oxalate	Escitalopram Oxalate	54	16
Tamsulosin Hcl	Tamsulosin Hcl	54	15
Dropsafe Prep Pads	Alcohol Antiseptic Pads	51	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	50	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	48	12
Carvedilol	Carvedilol	46	16
Ezetimibe	Ezetimibe	46	14
Clopidogrel	Clopidogrel Bisulfate	44	14
Glimepiride	Glimepiride	44	suppressed
Meloxicam	Meloxicam	44	20
Zolpidem Tartrate	Zolpidem Tartrate	43	suppressed
Buspirone Hcl	Buspirone Hcl	41	16
Clonazepam	Clonazepam	40	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	39	suppressed
Tizanidine Hcl	Tizanidine Hcl	36	suppressed
Chlorthalidone	Chlorthalidone	33	11
Olmesartan Medoxomil	Olmesartan Medoxomil	33	suppressed
Alprazolam	Alprazolam	32	suppressed
Promethazine Hcl	Promethazine Hcl	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	13
Dicyclomine Hcl	Dicyclomine Hcl	30	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Tramadol Hcl	Tramadol Hcl	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Labetalol Hcl	Labetalol Hcl	28	suppressed
Ondansetron Hcl	Ondansetron Hcl	28	13
Triamcinolone Acetonide	Triamcinolone Acetonide	28	15
Doxazosin Mesylate	Doxazosin Mesylate	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Linzess	Linaclotide	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	23	suppressed
Atenolol	Atenolol	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Glipizide	Glipizide	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Estradiol	Estradiol	20	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Ramipril	Ramipril	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Spironolactone	Spironolactone	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Eliquis	Apixaban	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	14	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Baclofen	Baclofen	13	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	13	suppressed
Topiramate	Topiramate	13	suppressed
Torsemide	Torsemide	13	suppressed
Valsartan	Valsartan	13	suppressed
Azithromycin	Azithromycin	12	12
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Estradiol (Twice Weekly)	Estradiol	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Matzim La	Diltiazem Hcl	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Cephalexin	Cephalexin	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Nystatin	Nystatin	11	suppressed
Repatha Sureclick	Evolocumab	11	suppressed
Spiriva Handihaler	Tiotropium Bromide	11	suppressed
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error